Guoguang Biotechnology stated today that it has accurately predicted 4 influenza virus strains this year, and has prepared SPF-free eggs for subculture, which can immediately enter the influenza vaccine production, which will ensure that this year’s influenza vaccine is fully supplied to the public and international Market order.
▲Guoguang Biotechnology stated on the 2nd that it accurately predicted 4 influenza virus strains this year, and is confident that it will enter the production schedule ahead of schedule this year, and the output can fully supply domestic and foreign influenza vaccine demand. (Photo/Central News Agency Information Photo)
At the end of February, the World Health Organization (WHO) announced the predicted virus candidate strains for influenza vaccine in the northern hemisphere this year, including two influenza A H1N1 and H3N2, and two influenza B Victoria strains (Victoria) and Yamagata strain (Yamagata), global vaccine factory This year’s flu vaccine will be produced accordingly.
Zhang Jinquan, Chief Operating Officer of Guoguang Biotechnology, said that although Taiwan is not a member of the WHO; however, Guoguang has obtained information on influenza viruses monitored by WHO globally by joining the International Pharmaceutical Production Alliance (IFPMA) affiliated to WHO, and continues to exchange information on influenza vaccines with major international manufacturers. . At present, IFPMA has 21 members worldwide, including international vaccine manufacturers Sanofi, GSK, etc. Guoguang is the only vaccine company in Taiwan that has joined IFPMA.
Zhang Jinquan pointed out that in response to the forecast of influenza vaccine virus strains, the WHO is developing high-yield virus strains in five countries including the United Kingdom, Australia, the United States, Japan and China. The WHO announces the northern hemisphere influenza vaccine virus strains in February and the southern hemisphere influenza vaccine virus strains in September.
Zhang Jinquan said that he has accumulated many years of experience in influenza virus prediction and vaccine production. This year, the two A plus two B virus strains have been accurately predicted. Specific pathogen-free eggs have been prepared, followed by subculture, and selected high-yield virus strains. Currently, they have entered the influenza vaccine stock solution. Production, it is possible to enter the production schedule ahead of schedule this year, and the output can fully supply domestic and foreign flu vaccine demand.
–
